Acurx Executives, Directors Take 10% Pay Cut Amid Cost-Cutting Efforts
Summary
Acurx Pharmaceuticals' President and CEO, Executive Chairman, and CFO, along with non-employee directors, have voluntarily agreed to a 10% reduction in their base salaries and cash retainers, effective April 1, 2026. For a micro-cap company trading near its 52-week low, these significant cost-cutting measures signal potential financial pressures or a strong imperative to conserve cash. While the company also announced a new clinical development initiative today, the executive pay cuts suggest a need for fiscal prudence that could concern investors. Traders will be watching for further financial disclosures to assess the company's liquidity and operational runway.
At the time of this announcement, ACXP was trading at $1.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.4M. The 52-week trading range was $1.33 to $21.00. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.